Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Liabilities and Shareholders Equity (2019 - 2025)

Avidity Biosciences' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 25.2% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $6.9 billion, up 25.74%, while the annual FY2025 figure was $2.0 billion, 25.2% up from the prior year.
  • Liabilities and Shareholders Equity reached $2.0 billion in Q4 2025 per RNA's latest filing, down from $2.1 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.1 billion in Q3 2025 to a low of $290.5 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $911.0 million, with a median of $621.3 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 18.24% in 2021, then soared 186.27% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $427.6 million in 2021, then soared by 49.4% to $638.8 million in 2022, then decreased by 1.6% to $628.6 million in 2023, then skyrocketed by 148.81% to $1.6 billion in 2024, then grew by 25.2% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Liabilities and Shareholders Equity are $2.0 billion (Q4 2025), $2.1 billion (Q3 2025), and $1.4 billion (Q2 2025).